 |  |
| ABX | ||
| 3,512.285 | ||
| 62.6000 | 0.0181% | |
| BISNIS-27 | ||
| 459.072 | ||
| 4.4910 | 0.0099% | |
| DBX | ||
| 3,169.828 | ||
| 25.1260 | 0.0080% | |
| ECONOMIC30 | ||
| 93.545 | ||
| 1.3240 | 0.0144% | |
| ESGQKEHATI | ||
| 110.164 | ||
| 1.0320 | 0.0095% | |
| ESGSKEHATI | ||
| 111.308 | ||
| 1.1240 | 0.0102% | |
| I-GRADE | ||
| 168.387 | ||
| 2.3980 | 0.0144% | |
| AUDRP | ||
| 12,707.540 | ||
| -19.0000 | -0.1493% | |
| EURRP | ||
| 20,459.820 | ||
| -41.1100 | -0.2005% | |
| JPYRP | ||
| 114.497 | ||
| 0.2404 | 0.2104% | |
| SINRP | ||
| 13,921.150 | ||
| -7.3100 | -0.0525% | |
| USDRP | ||
| 17,620.000 | ||
| -19.0000 | -0.1077% | |
Kandidat obat oral untuk pasien COVID-19 bertambah dengan kehadiran pil antivirus Paxlovid. Berdasarkan hasil sementara uji klinis fase II/III, Paxlovid menunjukkan hasil yang baik sehingga segera diajukan untuk mendapatkan izin penggunaan darurat.
